Sphingolipids in Alzheimer's disease, how can we target them?

Simone M. Crivelli, Caterina Giovagnoni, Lars Visseren, Anna-Lena Scheithauer, Nienke de Wit, Sandra den Hoedt, Mario Losen, Monique T. Mulder, Jochen Walter, Helga E. de Vries, Erhard Bieberich, Pilar Martinez-Martinez*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)214-231
Number of pages18
JournalAdvanced Drug Delivery Reviews
Volume159
DOIs
Publication statusPublished - 2020

Keywords

  • Ceramide
  • Sphingosine-1-phosphate (S1P)
  • Sphingomyelin (SM)
  • Alzheimer's disease
  • Blood brain barrier (BBB)
  • GW4869
  • Tricyclic dibenzoazepines (TCA)
  • Fingolimod (FTY720)
  • AMYLOID PRECURSOR PROTEIN
  • NERVE GROWTH-FACTOR
  • KINASE-C-ZETA
  • BLOOD-BRAIN-BARRIER
  • CERAMIDE SYNTHASE 2
  • SERINE PALMITOYLTRANSFERASE INHIBITOR
  • MITOCHONDRIAL OUTER-MEMBRANE
  • CULTURED HIPPOCAMPAL-NEURONS
  • P75 NEUROTROPHIN RECEPTOR
  • ANTIGEN-BINDING PROTEIN

Cite this